- Home
- / iCAD
iCAD
Stock Price
$1.9
2024-10-29
Market Capitalization
$50.1 M
2024-10-29
Revenue
$19.6 M
FY, 2024
iCAD Summary
Company Summary
- Overview
- iCAD is a company that specializes in developing AI-based solutions for early detection and risk assessment of breast cancer. It offers the ProFound suite for breast cancer detection, density assessment, and personalized risk evaluation. The company also develops VeraLook, a colon polyp detection tool that automatically identifies and highlights polyps in CTC images.
- Type
- Public
- Status
- Active
- HQ
- Nashua, NH, US | view all locations
- Website
- https://www.icadmed.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Stacey Stevens, Executive Vice President, Chief Strategy and Commercial Officer
Jonathan Go, Senior Vice President of Research & Development
LocationsView all
2 locations detected
Nashua, NH HQ
United States
98 Spit Brook Rd
San Jose, CA
United States
101 Nicholson Ln
iCAD Financials
Summary Financials
- Revenue (Q1, 2025)
- $4.9M
- Gross profit (Q1, 2025)
- $4.2M
- Net income (Q1, 2025)
- ($833.0K)
- Cash (Q1, 2025)
- $20.0M
- EBIT (Q1, 2025)
- ($1.1M)
- Enterprise value
- $30.3M